Home Tags Cancer: Prostate

Tag: Cancer: Prostate

Prostate-specific antigen levels three months after radiotherapy are strong markers of prostate cancer outcomes for patients with intermediate- and high-risk disease

PSA Level Three Months After Radiation Tx May Predict Outcome

Findings for men with intermediate- and high-risk prostate cancer
Fewer men are being screened for

From 2008 to 2014, Prostate Cancer Testing, Treatment Down

Sharpest decrease seen in privately insured men after 2011
Moderate wine consumption does not seem to impact the risk of prostate cancer

Overall, Drinking Wine Does Not Impact Prostate Cancer Risk

Findings show small increased risk with white wine, decreased risk with red wine
The U.S. Preventive Services Task Force concludes that the decision to undergo periodic prostate-specific antigen screening for prostate cancer should be an individual one for men aged 55 to 69 years. These findings form the basis of a final recommendation statement

USPSTF: Decision to Undergo PSA Screening Should Be Individual

C recommendation for men aged 55 to 69 years; USPSTF recommends against screening for age 70+
Men on androgen-deprivation therapy for prostate cancer may significantly benefit from a group exercise and nutrition program

Group Exercise, Nutrition Aids Prostate Cancer Patients on ADT

Improvements seen in mobility, body fat, muscle strength in men on androgen-deprivation therapy
For castration-resistant prostate cancer

Low-Dose Abiraterone Acetate Noninferior for Prostate Cancer

Low-dose AA with low-fat breakfast had greater effect on PSA; similar effect to standard dose
For men with a clinical suspicion of prostate cancer

MRI-Targeted Biopsy Noninferior for Prostate Cancer Detection

Clinically significant cancer detected in more men in MRI-targeted biopsy versus standard-biopsy group
Dose escalation from 70.2 to 79.2 Gy is not associated with improved overall survival in intermediate-risk prostate cancer

Dose-Escalated Radn Does Not Up Survival in Localized Prostate CA

No improvement in overall survival; no difference in cumulative rate of distant metastases
For men with metastatic prostate cancer there is no survival advantage for aggressive therapy over conservative androgen deprivation therapy only

No Benefit for Aggressive Therapy in Metastatic Prostate Cancer

However, mortality higher with conservative therapy in locally advanced, non-metastatic prostate cancer
A single prostate-specific antigen screening is not associated with a significant difference in prostate cancer mortality after follow-up of 10 years

Single PSA Screening Doesn’t Cut Prostate Cancer Mortality

But screening is associated with increased detection of low-risk prostate cancer